Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
暂无分享,去创建一个
W. Bonfig | S. Bechtold | H. Schwarz | H. Schmidt | D. Knorr
[1] F. Baronio,et al. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. , 2003, The Journal of clinical endocrinology and metabolism.
[2] C. Polychronakos,et al. Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency. , 2003, The Journal of pediatrics.
[3] M. V. van’t Hof,et al. Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty. , 2003, The Journal of clinical endocrinology and metabolism.
[4] V. Tardy,et al. Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management. , 2003, The Journal of clinical endocrinology and metabolism.
[5] Perrin C White,et al. Congenital adrenal hyperplasia. , 2003, The New England journal of medicine.
[6] C. Kanaka-Gantenbein,et al. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome , 2002, Clinical endocrinology.
[7] H. Guyda,et al. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. , 2002, The Journal of pediatrics.
[8] M. Jansen,et al. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients , 2002, Archives of disease in childhood.
[9] T. Battelino,et al. Congenital Adrenal Hyperplasia: Lessons from a Multinational Study , 2002, Hormone Research in Paediatrics.
[10] T. Battelino,et al. Growth Patterns and Final Height in Congenital Adrenal Hyperplasia due to Classical 21-Hydroxylase Deficiency , 2001, Hormone Research in Paediatrics.
[11] M. Vogiatzi,et al. Long term outcome in adult males with classic congenital adrenal hyperplasia. , 2001, The Journal of clinical endocrinology and metabolism.
[12] L. Dimeglio,et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. , 2001, The Journal of pediatrics.
[13] S. Rivkees,et al. Dexamethasone Treatment of Virilizing Congenital Adrenal Hyperplasia: The Ability to Achieve Normal Growth , 2000, Pediatrics.
[14] A. Braun,et al. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. , 2000, The Journal of clinical endocrinology and metabolism.
[15] W. Greulich,et al. Radiographic Atlas of Skeletal Development of the Hand and Wrist , 1999 .
[16] I. Hughes. Congenital adrenal hyperplasia—a continuum of disorders , 1998, The Lancet.
[17] I. Hughes,et al. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience , 1997, Clinical endocrinology.
[18] R. Voutilainen,et al. Growth of Patients with 21-Hydroxylase Deficiency: An Analysis of the Factors Influencing Adult Height , 1997, Pediatric Research.
[19] D. Merke,et al. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. , 1996, The Journal of clinical endocrinology and metabolism.
[20] D. Grant,et al. Adult height in women with early‐treated congenital adrenal hyperplasia (21‐hydroxylase type): relation to body mass index in earlier childhood , 1995, Acta paediatrica.
[21] T J Cole,et al. Body mass index reference curves for the UK, 1990. , 1995, Archives of disease in childhood.
[22] J. Devesa,et al. Regulation of hypothalamic somatostatin by glucocorticoids , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[23] R. Lala,et al. Auxological and biochemical parameters in assessing treatment of infants and toddlers with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 1993, The Journal of pediatric endocrinology.
[24] G. Cutler,et al. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 1990, The New England journal of medicine.
[25] I. Hughes,et al. Growth and body proportions in congenital adrenal hyperplasia. , 1989, Archives of disease in childhood.
[26] L. Molinari,et al. Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. , 1989, Helvetica paediatrica acta. Supplementum.
[27] M. New,et al. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. , 1989, Journal of endocrinological investigation.
[28] C. Migeon,et al. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 1987, The New England journal of medicine.
[29] M. New,et al. The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH). , 1986 .
[30] R. Largo,et al. Pubertal development in Swiss girls. , 1983, Helvetica paediatrica acta.
[31] R. Largo,et al. Pubertal development in Swiss boys. , 1983, Helvetica paediatrica acta.
[32] I. Hughes,et al. Menarche and subsequent ovarian function in girls with congenital adrenal hyperplasia. , 1982 .
[33] S. Duck. Acceptable linear growth in congenital adrenal hyperplasia. , 1980, The Journal of pediatrics.
[34] P. A. Lee,et al. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. , 1978, The New England journal of medicine.
[35] J. Holcombe,et al. The effect of therapy on mature height in congenital adrenal hyperplasia. , 1978, The Journal of clinical endocrinology and metabolism.
[36] C. Migeon,et al. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. , 1977, The Journal of pediatrics.